SARS-CoV-2 aptasensor based on electrochemical impedance spectroscopy and low-cost gold electrode substrates

Lasserre, Perrine and Balansethupathy, Banushan and Vezza, Vincent J. and Butterworth, Adrian and Macdonald, Alexander and Blair, Ewen O. and McAteer, Liam and Hannah, Stuart and Ward, Andrew C. and Hoskisson, Paul A. and Longmuir, Alistair and Setford, Steven and Farmer, Eoghan C. W. and Murphy, Michael E. and Flynn, Harriet and Corrigan, Damion K. (2022) SARS-CoV-2 aptasensor based on electrochemical impedance spectroscopy and low-cost gold electrode substrates. Analytical Chemistry, 94 (4). 2126–2133. ISSN 0003-2700 (https://doi.org/10.1021/acs.analchem.1c04456)

[thumbnail of Lasserre-etal-AC-2021- A-SARS-CoV-2-aptasensor-based-on-electrochemical-impedance-spectroscopy]
Preview
Text. Filename: Lasserre_etal_AC_2021_A_SARS_CoV_2_aptasensor_based_on_electrochemical_impedance_spectroscopy.pdf
Final Published Version
License: Creative Commons Attribution 4.0 logo

Download (2MB)| Preview

Abstract

SARS-CoV-2 diagnostic practices broadly involve either quantitative polymerase chain reaction (qPCR)-based nucleic amplification of viral sequences or antigen-based tests such as lateral flow assays (LFAs). Reverse transcriptase-qPCR can detect viral RNA and is the gold standard for sensitivity. However, the technique is time-consuming and requires expensive laboratory infrastructure and trained staff. LFAs are lower in cost and near real time, and because they are antigen-based, they have the potential to provide a more accurate indication of a disease state. However, LFAs are reported to have low real-world sensitivity and in most cases are only qualitative. Here, an antigen-based electrochemical aptamer sensor is presented, which has the potential to address some of these shortfalls. An aptamer, raised to the SARS-CoV-2 spike protein, was immobilized on a low-cost gold-coated polyester substrate adapted from the blood glucose testing industry. Clinically relevant detection levels for SARS-CoV-2 are achieved in a simple, label-free measurement format using sample incubation times as short as 15 min on nasopharyngeal swab samples. This assay can readily be optimized for mass manufacture and is compatible with a low-cost meter.